Objectives Despite their use, differences in human papillomavirus (HPV) vaccine efficacies
remain uncertain. This study assesses efficacy differences among bivalent, quadrivalent …

BACKGROUND: Vaccines are now available for the prevention of HPV-16/18-related
cervical infections and pre-cancers, primarily targeting adolescent girls. Since the risk of …

Background Cervical cancer and its obligate precursors, cervical intraepithelial neoplasia
grades 2 and 3 (CIN2/3), and adenocarcinona in situ (AIS), are caused by oncogenic human …

The efficacy and immunogenicity of human papillomavirus (HPV) vaccines has proven
excellent in several phase 2 and phase 3 trials involving tens of thousand women. Two …

The AS04-adjuvanted human papillomavirus (HPV) 16/18 vaccine (Cervarix®) is a
noninfectious recombinant vaccine produced using purified virus-like particles (VLPs) that …

Aim: India has the highest number of annual incident cases and mortality rates for cervical
cancer worldwide. This study was conducted to assess the immunogenicity and safety of …

Background Anal cancer remains rare (incidence of about 1· 5 per 100 000 women yearly),
but rates are increasing in many countries. Human papillomavirus (HPV) 16 and 18 …

Background We conducted a systematic review and meta-analysis to assess efficacy and
safety of prophylactic HPV vaccines against cervical cancer precursor events in women …

Persistent infection with human papillomavirus (HPV) is a necessary cause of cervical
cancer, resulting annually in 274,000 deaths worldwide. Two prophylactic HPV vaccines are …

Efficacy, immunogenicity and tolerability of the human papillomavirus (HPV)‐16/18 AS04‐
adjuvanted vaccine were evaluated in Japanese women aged 20–25 years, for which …